Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population

PACE - Pacing and Clinical Electrophysiology

Volumn 33, Issue 6, 2010, Pages 696-704

  Obeyesekere, Manoj N ^a   Chan, William ^a   Stub, Dion ^a   Prabhu, S ^a   Teo, Eliza P ^a   Toogood, Geoff ^a   Mariani, Justin ^a   Broughton, Archer ^a   Kistler, Peter M ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Congestive heart failure; Defibrillation ICD

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR;

ADULT; ARTICLE; DEATH; DEFIBRILLATOR; DEVICE INFECTION; DEVICE PERFORATION; DEVICE REMOVAL; DEVICE THERAPY; ENDOCARDITIS; EVENT FREE SURVIVAL; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HEMATOMA; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PACEMAKER FAILURE; PRIMARY PREVENTION; TREATMENT OUTCOME; AGED; CARDIOMYOPATHIES; DEATH, SUDDEN, CARDIAC; DRUG EFFECTS; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MIDDLE AGED; PHYSIOLOGY; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOMYOPATHIES; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; STROKE VOLUME; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FIBRILLATION; VENTRICULAR FUNCTION, LEFT;

EID: 77953223681     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2009.02669.x     Document Type: Article

References (30)

1. Tham TJ, Kannel WB, Silbershatz H, D'Agostino RB. In Fuster V, et al eds. Hurst's The Heart, Arteries and Veins. 10th ed. New York, NY, McGraw-Hill, 2001, pp. 3-17.
2. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, et al, for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 346:877-883.
3. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 352:225-237.
4. Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, et al. Predictors of sudden cardiac death and appropriate shock in the comparison of medical therapy, pacing, and defibrillation in heart failure (COMPANION) Trial. Circulation 2006 114:2766-2772.
5. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Reddy RK, et al. Prognostic importance of defibrillator shocks in patients with heart failuire. N Engl J Med 2008 359:1009-1017.
6. Sears SF, Todaro JF, Urizar G, Lewis TS, Sjrois B, Wallace R, Sotile W, et al. Assessing the psychosocial impact of the ICD: A national survey of implantable cardioverter defibrillator health care providers. Pacing Clin Electrophysiol 2000 23:939-945.
7. Kleemann T, Becker T, Doenges K, Vater M, Senges J, Schneider S, Saggau W, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation 2007 115:2474-2480.
8. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MB, Daubert JP, et al, for the Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group. Long-term clinical course of patients after termination of ventricular tachyarrhthmia by an implanted defibrillator. Circulation 2004 110:3760-3765.
9. Koller MT, Schaer B, Wolbers M, Sticherling C, Bucher HC, Osswald S. Death without prior appropriate implantable cardioverter-defibrillator therapy - a competing risk study. Circulation 2008 117:1918-1926.
10. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, et al. Investigators of the AVID, CASH and CIDS studies. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 2000 21:2071-2078.
11. Klein G, Lissel C, Fuchs AC, Gardiwal A, Oswald H, DeSousa M, Pichlmaier AM, et al. Predictors of VT/VF-occurrence in ICD patients: Results from the PROFIT-Study. Europace 2006 8:618-624.
12. Whang W, Mittleman MA, Rich DQ, Wang PJ, Ruskin JN, Tofler GH, Muller JE, et al, for the TOVA Investigators. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators results from the triggers of ventricular arrhythmias (TOVA) study. Circulation 2004 109:1386-1391.
13. Singh JP, Hall WJ, McNitt S, Wang H, Daubert JP, Zareba W, Ruskin JN, et al. The MADIT-II investigators. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation findings from the multicenter automatic defibrillator implantation trial II (MADIT-II). J Am Coll Cardiol 2005 46:1712-1720.
14. Grimm W, Christ M, Bach J, Müller H, Maisch B. Non invasive risk stratification in idiopathic dilated cardiomyopathy. Results of the Marburg cardiomyopathy study. Circulation 2003 108:2883-2891.
15. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel J-P. Clinical effects of β-adrenergic blockade in chronic heart failure a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998 98:1184-1191.
16. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, et al, for the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: Results of the CHARM Low-Left Ventricular Ejection Fraction Trials. Circulation 2004 110:2618-2626.
17. Bristow MR. ß-adrenergic receptor blockade in chronic heart failure. Circulation 2000 101:558-569.
18. Maisel WH, Stevenson WG. Sudden death and the electrophysiological effects of angiotensin-converting enzyme inhibitors. J Card Fail 2000 6:80-82.
19. Mitchell LB. Role of drug therapy for sustained ventricular tachyarrhythmias. Cardiol Clin 2008 26:405-418.
20. Jugdutt BI, Lucas A, Khan MI. Effect of angiotensin-converting enzyme inhibition on infarct collagen deposition and remodeling during healing after transmural canine myocardial infarction. Can J Cardiol 1997 13:657-668.
21. Ertel SI, Ertel EA, Clozel J-P. T-Type Ca21 channels and pharmacological blockade: Potential pathophysiological relevance. Cardiovasc Drugs Ther 1997 11:723-739.
22. Allen IS, Cohen NM, Dhallan RS, Gaa ST, Lederer WJ, Rogers TB. Angiotensin II increases spontaneous contractile frequency and stimulates calcium current in cultured neonatal rat heart myocytes: Insights into the underlying biochemical mechanisms. Circ Res 1988 62:524-534.
23. + channel current by angiotensin II in rabbit ventricular myocytes. Circ Res 1994 75:1121-1125.
24. Hattori Y, Atsushi S, Hiroaki F, Toyama J. Effects of captopril on ventricular arrhythmias in patients with congestive heart failure. Clin Ther 1997 19:481-486.
25. Webster MWI, Fitzpatrick A, Nicholls G, Ikram H, Wells JE. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol 1985 56:566-569.
26. Garg R, Yusuf S, Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995 273:1450-1456.
27. Germano JJ, Reynolds M, Essebag V, Josephson ME. Frequency and causes of implantable cardioverter-defibriallator therapies: Is device therapy proarrhthmic? Am J Cardiol 2006 97:1255-1261.
28. Ellenbogen KA, Levine JH, Berger RD, Daubert JP, Winters SL, Greenstein E, Shalaby A, et al, for the Defibrillators in Non- Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Are implantable cardioverter defibrillator shocks a suirrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation 2006 113:776-782.
29. Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RO, et al, for the PainFREE Rx II Investigators. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (Pain- FREE Rx II) trial results. Circulation 2004 110:2591-2596.
30. Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lee FLS, Birgersdotter-Green UM, Wathen MS, et al. and PREPARE Study Investigators. Strategic programming of detection and therapy parameters in Implantable Cardioverter-Defibrillators Reduces Shocks in primary prevention patients; Results from the PREPARE (Primary Prevention Parameters Evaluation) Study. J Am Coll Cardiol 2008 52:541-550.